NextCell Pharma AB (NextCell) today treated the last diabetic patient in the phase II part of the ProTrans-1 trial. This means that all patients included in the clinical study have been treated and are now subject to a 12-month follow-up period before efficacy and safety data will be available.
The final patient has been treated in the randomized, placebo controlled ProTrans-1 phase II part trial. Efficacy and safety data will be collected through regular clinical assessments visits during a 12 month period. Last patient, last will be assessed in July 2020 and thereafter the code will be broken, i.e. which patient received the study drug and which received placebo, and effect analysis can be conducted. Efficacy and safety data are expected to be published in Q3 2020.
At the end of May, NextCell’s second study, ProTans Repeat, started to evaluate the effect of repeated treatment with ProTrans and will be parallel to ProTrans-1. In order to give a more detailed update on the clinical trials and process we have created a concise schematic showing how our clinical trials has developed over time and when study completion can be expected.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 20 June 2019.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
